HIGHBuilt-inGeographic
74%
outside United States
“10-K Item 1: 'approximately 74% of our 2025 revenues, or $4.6 billion, generated outside the United States'”
OGN · Concentration risk · 10-K extracted
Organon & (OGN) concentration risks
Updated
The most significant concentration Organon & discloses is outside United States at 74%, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Organon &’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 3 disclosed concentrations
HIGH2
MEDIUM0
LOW1
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHBuilt-inProduct / Revenue mix
59%
Established Brands
“10-K Item 1: 'Established Brands... this portfolio contributed approximately $3.7 billion, or approximately 59% of our total revenues'”
LOWOutside partySupplier
Samsung Bioepis and Henlius
“10-K Item 1A: 'We rely on our commercialization agreements with Samsung Bioepis, Henlius and Biothera for the successful development and manufacture of our biosimilars products'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-06-24The company's concentration profile spans geography, product mix, and the supply chain. The most significant disclosed exposure is geographic: approximately 74% of 2025 revenues — or $4.6 billion — were generated outside the United States, a high-share structural concentration. The international orientation reflects a deliberate market strategy targeting established and emerging markets globally, but it also means results are highly exposed to foreign-exchange translation, regional macroeconomic cycles, and international regulatory dynamics. On the product side, the Established Brands portfolio — mature branded pharmaceutical products — contributed approximately $3.7 billion, or approximately 59% of total revenues. This is a high-share structural concentration, and its character reflects the company's dependence on a portfolio of off-patent or near-patent-expiry products for the majority of its revenue base. Established brands face secular volume pressure from generic substitution and price erosion over time, making revenue durability a key structural question. The supply chain carries a low-share dependency: the company relies on commercialization agreements with Samsung Bioepis, Henlius, and Biothera for the development and manufacture of its biosimilars products. While small in relative share, these relationships are dependency-driven — third-party manufacturing and commercialization agreements introduce execution and contractual risk that differs from internally controlled supply chains. Together, the international revenue base and Established Brands concentration are the dominant variables, with biosimilar partner dependencies as a secondary consideration.
For the engine’s reasoning on OGN’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Drug Manufacturers - General
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ABBV | AbbVie Inc. | 2 | 1 | 0 | 3 |
| OGN● | Organon & Co. | 2 | 0 | 1 | 3 |
| AMGN | Amgen Inc. | 2 | 0 | 0 | 2 |
| GILD | Gilead Sciences, Inc. | 1 | 1 | 0 | 2 |
| BMY | Bristol-Myers Squibb Company | 1 | 0 | 0 | 1 |
| BIIB | Biogen Inc. | 0 | 0 | 2 | 2 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.